此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

人类疼痛实验模型(HEMP)

一项开发两种镇痛药作用机制和镇痛效果综合信号检测方法的初步研究,使用人类疼痛实验模型(HEMP)

This pilot study will test an innovative way to establish how pain medicines provide analgesia in healthy adults. The study uses a group of short, controlled pain tests to look at different types of pain responses in the body. The main goal is to find out if this testing approach can show the pain-relieving effects of 2 medicines, pregabalin and naproxen versus placebo, and show how they provide relief of different types of pain.

The study hypothesis is that this pain testing approach administered as a battery would be able to tell the difference between a medicine that works mainly in the brain and spinal cord (pregabalin) and a medicine that works mainly on inflammation in body tissues (naproxen).

Up to 25 healthy adults will take part. Each participant will receive all 3 study treatments, pregabalin, naproxen, and placebo, administered in random order during separate study periods. The order will be assigned by chance. Neither the participant nor the study team will know which treatment is given at each visit.

The study includes several experimental pain tests. These include:

a heat and capsaicin skin test that causes short-term skin sensitivity,

a UVB light test that causes a temporary sunburn-like sensitivity, and

a cold pressor test, in which a hand is placed in very cold water for a short time.

Participants will also have sensory testing to measure how they feel touch, pressure, pinprick, warmth, heat, and cold. Blood samples will be collected to measure study drug levels. Urine samples, vital signs, and other safety checks will also be done.

Each treatment visit includes testing before and for several hours after taking the study drug. There will be a washout period of at least 48 hours between treatments. Total participation may last up to about 10 weeks.

This study is not expected to provide direct medical benefit to participants. The information learned may help researchers improve early testing of future pain treatments....

研究概览

详细说明

Study Description:

This pilot study is designed to validate the performance characteristics of HEMP. This pilot study is a single-center, randomized, double-blind, three-period, three-treatment crossover designed to investigate how well the HEMP model distinguishes the analgesic properties of two medications, one which acts centrally and the other one acts peripherally.

Up to 25 healthy adults will be enrolled in this study, which will consist of a screening phase and a treatment phase with three periods. Participants will be randomly assigned to receive either a gabapentinoid (pregabalin), a non-steroidal anti-inflammatory drug (NSAID) (naproxen), or a placebo during each period of the treatment phase (see Table 2 for the study drugs). Each dose will be separated by a wash-out period of at least 48 hours.

Assessments will be performed at baseline and over a period of 8 hours following each drug administration to establish pharmacodynamic, pharmacokinetic, and safety properties of the treatments.

Objectives:

Primary Objective:

To establish the ability of HEMP to demonstrate the analgesic efficacy of pregabalin and naproxen based on their known mechanisms of action (central vs. peripheral, respectively) as measured by the severity of experimental pain, allodynia, and hyperalgesia across three pain models.

Secondary Objectives:

To demonstrate that HEMP can determine factors that differentiate responders from non-responders to the study drugs, when evaluating their analgesic properties of these drugs in humans.

Endpoints:

Pharmacodynamics (PD) Primary Endpoint:

  • Change from baseline in pain intensity (PI) visual analog scale (VAS) score for allodynia (soft brush) after first heat/capsaicin application (HCM)
  • Change from baseline in PI VAS score for hyperalgesia (pin-prick) after first HCM
  • Change from baseline in PI VAS score for hyperalgesia (pin-prick) ultraviolet (UVB) light exposure.
  • Change from baseline in PI VAS score for heat hyperalgesia (thermal-heat pain) UVB
  • Change from baseline in PI VAS score after hand removal in Cold Pressor Test (CPT), i.e., cold water immersion

Secondary Endpoints:

  • Weighted mean (based on area under the curve (AUC)) VAS score for spontaneous pain over 0-60 mins following first and second HCM.
  • Area of secondary hyperalgesia to pin-pick after HCM following first and second HCM
  • Change from baseline in PI VAS score for thermal-heat hyperalgesia following first and second HCM
  • Proportion of participant who had at least 30% reduction in PI VAS scores from baseline after a Quantitative Sensory Testing (QST) measure (soft brush, light pressure, pin-prick, thermal contact- warm, thermal contact-heat pain, cold) after first and second HCM and UVB PK parameters (e.g., AUClast, Clast, Cmax, tmax)

研究类型

介入性

注册 (估计的)

25

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Maryland
      • Bethesda、Maryland、美国、20892
        • National Institutes of Health Clinical Center
        • 接触:
          • NIH Clinical Center Office of Patient Recruitment (OPR)
          • 电话号码:TTY dial 711 800-411-1222
          • 邮箱:ccopr@nih.gov

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 100年 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

描述

  • INCLUSION CRITERIA:

For an individual to be eligible to participate in this study, they must meet all of the following criteria:

  • Voluntarily consent to participate and provide written informed consent prior to the start of any study-specific procedures.
  • Read and speak English fluently.
  • State willingness to comply with all study procedures and availability for the duration of the study.
  • Are not pregnant or breastfeeding.
  • Are 18 or older years of age at screening.
  • Have a skin type score between 2 and 5 (inclusive) on the Fitzpatrick Scale.
  • Must correctly identify at least nine out of 12 temperatures (32 degrees Celsius, 38 degrees Celsius, 44 degrees Celsius, and 50 degrees Celsius, each presented three times) during the sensory discrimination test at screening.
  • Provide a verbal pain rating between 4 and 9 (inclusive) during the intradermal capsaicin challenge at screening. The study team will verify tolerability, and participants will continue only after it has been confirmed.
  • During the cold pressor test at screening, provide a verbal pain rating between 4 and 9 (inclusive) and keep one hand completely immersed in ice-cold water (1-4 degrees Celsius) between 1 and 4 minutes (inclusive). The study team will verify tolerability, and participants will continue only after it has been confirmed.
  • Are able to learn and perform all quantitative sensory testing QST procedures (see the separate QST manual).
  • Have the ability to take oral medication and be willing to adhere to the study intervention regimen.

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

  • Have a history or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, oncologic, or psychiatric disease or any other condition that, in the opinion of the Investigator, would jeopardize the safety of the participant or the validity of the study results.
  • Have alcohol or drug dependence (excluding nicotine and caffeine) within the past 2 years, as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision (DSM IV-TR) and/or participants who have ever been in a substance or alcohol rehabilitation program to treat their substance dependence are currently seeking such treatment.
  • Have a clinically significant abnormal finding on the physical exam, medical history, or clinical laboratory results at screening.
  • Have a history of psychotic reactions, a non-psychotic emotional disorder, or another mental illness that, in the opinion of the investigator, may affect the ability of the participant to participate in the study.
  • Have recent history of suicidal ideation or suicidal behavior within the past 6 months, as assessed by the Columbia- Suicide Severity Rating Scale (C-SSRS) at screening (baseline version) or at check-in ( Since Last Visit version).
  • Have a history of allergy or hypersensitivity to pregabalin or other gabapentinoids, naproxen or other NSAIDs, or another ingredient in the study drugs, or anything else that, in the opinion of the Investigator, could put the participant at risk.
  • Have participated in another clinical trial (randomized participants only) within 30 days prior to the first dose of study medication.
  • Use any prescription medication, except hormonal contraceptive or hormonal replacement therapy, from 14 days prior to the first dose of study medication until study participation has ended without evaluation and approval by the Investigator.
  • Donate blood or plasma within 30 days prior to the first dose of study medication until the end of study participation. It is recommended that participants not donate blood or plasma until at least 30 days after their study participation has ended.
  • Female participants who are currently pregnant or breastfeeding, or who are planning to become pregnant during the study or within 30 days after the last study drug administration.
  • Show a positive urine alcohol test at screening.
  • Have smoked or used tobacco- or nicotine-containing products within 30 days prior to the first dose of study treatment until the end of the study.
  • Have an allergy to capsaicin or another capsaicinoid.
  • Have a tattoo, excessive scarring or discoloration, keloid formation, or, at the Investigator s discretion, otherwise unhealthy skin (e.g., eczema, psoriasis, burn, and cut) at a QST site.
  • Have a significant history of nerve injury or damage at a QST site, at the Investigator s discretion.
  • Participants who report any stimulus as intolerable at any point during the screening procedures will be excluded from participation.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:基础科学
  • 分配:随机化
  • 介入模型:交叉作业
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
实验性的:Sequence ABC (Pregabalin - Naproxen - Placebo)

Participants assigned to this sequence will receive single-dose oral pregabalin 300 mg in Period 1, naproxen 550 mg in Period 2, and matching placebo in Period 3. Treatment periods are separated by at least 48 hours.

Over-encapsulated matching placebo administered as a single oral dose in one treatment period of this randomized, double-blind, 3-period crossover study. The placebo is made to look identical to active study drug capsules to maintain blinding. Each participant receives placebo once, with at least 48 hours washout between treatment periods.

Over-encapsulated oral naproxen, 550 mg, administered as a single dose in one treatment period of this randomized, double-blind, 3-period crossover study. Each participant receives naproxen once, with at least 48 hours washout between treatment periods.

Over-encapsulated oral pregabalin, 300 mg, administered as a single dose in one treatment period of this randomized, double-blind, 3-period crossover study. Each participant receives pregabalin once, with at least 48 hours washout between treatment periods.

实验性的:Sequence ACB (Pregabalin - Placebo - Naproxen)

Participants assigned to this sequence will receive single-dose oral pregabalin 300 mg in Period 1, matching placebo in Period 2, and naproxen 550 mg in Period 3. Treatment periods are separated by at least 48 hours.

Over-encapsulated matching placebo administered as a single oral dose in one treatment period of this randomized, double-blind, 3-period crossover study. The placebo is made to look identical to active study drug capsules to maintain blinding. Each participant receives placebo once, with at least 48 hours washout between treatment periods.

Over-encapsulated oral naproxen, 550 mg, administered as a single dose in one treatment period of this randomized, double-blind, 3-period crossover study. Each participant receives naproxen once, with at least 48 hours washout between treatment periods.

Over-encapsulated oral pregabalin, 300 mg, administered as a single dose in one treatment period of this randomized, double-blind, 3-period crossover study. Each participant receives pregabalin once, with at least 48 hours washout between treatment periods.

实验性的:Sequence BAC (Naproxen - Pregabalin - Placebo)

Participants assigned to this sequence will receive single-dose oral naproxen 550 mg in Period 1, pregabalin 300 mg in Period 2, and matching placebo in Period 3. Treatment periods are separated by at least 48 hours.

Over-encapsulated matching placebo administered as a single oral dose in one treatment period of this randomized, double-blind, 3-period crossover study. The placebo is made to look identical to active study drug capsules to maintain blinding. Each participant receives placebo once, with at least 48 hours washout between treatment periods.

Over-encapsulated oral naproxen, 550 mg, administered as a single dose in one treatment period of this randomized, double-blind, 3-period crossover study. Each participant receives naproxen once, with at least 48 hours washout between treatment periods.

Over-encapsulated oral pregabalin, 300 mg, administered as a single dose in one treatment period of this randomized, double-blind, 3-period crossover study. Each participant receives pregabalin once, with at least 48 hours washout between treatment periods.

实验性的:Sequence BCA (Naproxen - Placebo - Pregabalin)

Participants assigned to this sequence will receive single-dose oral naproxen 550 mg in Period 1, matching placebo in Period 2, and pregabalin 300 mg in Period 3. Treatment periods are separated by at least 48 hours.

Over-encapsulated matching placebo administered as a single oral dose in one treatment period of this randomized, double-blind, 3-period crossover study. The placebo is made to look identical to active study drug capsules to maintain blinding. Each participant receives placebo once, with at least 48 hours washout between treatment periods.

Over-encapsulated oral naproxen, 550 mg, administered as a single dose in one treatment period of this randomized, double-blind, 3-period crossover study. Each participant receives naproxen once, with at least 48 hours washout between treatment periods.

Over-encapsulated oral pregabalin, 300 mg, administered as a single dose in one treatment period of this randomized, double-blind, 3-period crossover study. Each participant receives pregabalin once, with at least 48 hours washout between treatment periods.

实验性的:Sequence CAB (Placebo - Pregabalin - Naproxen)

Participants assigned to this sequence will receive matching placebo in Period 1, pregabalin 300 mg in Period 2, and naproxen 550 mg in Period 3. Treatment periods are separated by at least 48 hours.

Over-encapsulated matching placebo administered as a single oral dose in one treatment period of this randomized, double-blind, 3-period crossover study. The placebo is made to look identical to active study drug capsules to maintain blinding. Each participant receives placebo once, with at least 48 hours washout between treatment periods.

Over-encapsulated oral naproxen, 550 mg, administered as a single dose in one treatment period of this randomized, double-blind, 3-period crossover study. Each participant receives naproxen once, with at least 48 hours washout between treatment periods.

Over-encapsulated oral pregabalin, 300 mg, administered as a single dose in one treatment period of this randomized, double-blind, 3-period crossover study. Each participant receives pregabalin once, with at least 48 hours washout between treatment periods.

实验性的:Sequence CBA (Placebo - Naproxen - Pregabalin)

Participants assigned to this sequence will receive matching placebo in Period 1, naproxen 550 mg in Period 2, and pregabalin 300 mg in Period 3. Treatment periods are separated by at least 48 hours.

Over-encapsulated matching placebo administered as a single oral dose in one treatment period of this randomized, double-blind, 3-period crossover study. The placebo is made to look identical to active study drug capsules to maintain blinding. Each participant receives placebo once, with at least 48 hours washout between treatment periods.

Over-encapsulated oral naproxen, 550 mg, administered as a single dose in one treatment period of this randomized, double-blind, 3-period crossover study. Each participant receives naproxen once, with at least 48 hours washout between treatment periods.

Over-encapsulated oral pregabalin, 300 mg, administered as a single dose in one treatment period of this randomized, double-blind, 3-period crossover study. Each participant receives pregabalin once, with at least 48 hours washout between treatment periods.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change from baseline in pain intensity after cold pressor test
大体时间:Baseline and approximately 2, 5, and 8 hours after dosing in each treatment period

Change from baseline in participant-rated pain intensity VAS score measured immediately after hand removal from cold water during the cold pressor test (CPT). Higher scores indicate greater pain intensity.

Baseline and approximately 2, 5, and 8 hours after dosing in each treatment period
Change from baseline in pain intensity for allodynia (soft brush) after first heat/capsaicin pain model application
大体时间:Baseline and approximately 2, 5, and 8 hours after dosing in each treatment period

Change from baseline in participant-rated pain intensity VAS score for soft-brush allodynia at the heat/capsaicin pain model (HCM) site after the first HCM application. Higher scores indicate greater pain intensity.

Baseline and approximately 2, 5, and 8 hours after dosing in each treatment period
Change from baseline in pain intensity for hyperalgesia (pin-prick) after first heat/capsaicin pain model application
大体时间:Baseline and approximately 2, 5, and 8 hours after dosing in each treatment period

Change from baseline in participant-rated pain intensity VAS score for pin-prick hyperalgesia at the HCM site after the first HCM application. Higher scores indicate greater pain intensity.

Baseline and approximately 2, 5, and 8 hours after dosing in each treatment period
Change from baseline in pain intensity for mechanical hyperalgesia (pin-prick) at the UVB site
大体时间:Baseline and approximately 2, 5, and 8 hours after dosing in each treatment period

Change from baseline in participant-rated pain intensity VAS score for pin-prick hyperalgesia at the UVB-treated skin site. Higher scores indicate greater pain intensity.

Baseline and approximately 2, 5, and 8 hours after dosing in each treatment period
Change from baseline in pain intensity for thermal hyperalgesia (heat pain) at the UVB site
大体时间:Baseline and approximately 2, 5, and 8 hours after dosing in each treatment period

Change from baseline in participant-rated pain intensity VAS score for thermal-heat pain hyperalgesia at the UVB-treated skin site. Higher scores indicate greater pain intensity.

Baseline and approximately 2, 5, and 8 hours after dosing in each treatment period

次要结果测量

结果测量
措施说明
大体时间
Weighted mean pain intensity VAS score for spontaneous pain over 0 to 60 minutes following first and second HCM applications
大体时间:0 to 60 minutes after the first and second HCM applications during each treatment period

Weighted mean spontaneous pain visual analog scale (VAS) score calculated using area under the curve (AUC) over 60 minutes after each HCM application. Higher scores indicate greater spontaneous pain.

0 to 60 minutes after the first and second HCM applications during each treatment period
Area of secondary hyperalgesia to pin-prick following first and second HCM applications
大体时间:After the first and second HCM applications during each treatment period

Size of the mapped area of secondary pin-prick hyperalgesia at the HCM site after each HCM application. Larger area indicates greater secondary hyperalgesia.

After the first and second HCM applications during each treatment period
Change from baseline in pain intensity VAS score for thermal-heat hyperalgesia following first and second HCM applications
大体时间:Baseline and approximately 2, 5, and 8 hours after dosing in each treatment period

Change from baseline in participant-rated pain intensity VAS score for thermal-heat pain hyperalgesia at the HCM site after first and second HCM applications. Higher scores indicate greater pain intensity.

Baseline and approximately 2, 5, and 8 hours after dosing in each treatment period
Proportion of participants with at least 30% reduction from baseline in pain intensity VAS score after QST measures at HCM and UVB sites
大体时间:Baseline and approximately 2, 5, and 8 hours after dosing in each treatment period

Proportion of participants with at least 30% reduction from baseline in pain intensity VAS score after quantitative sensory testing (QST) modalities, including soft brush, light pressure, pin-prick, warm, heat pain, and cold, at HCM and UVB sites.

Baseline and approximately 2, 5, and 8 hours after dosing in each treatment period
Pharmacokinetic parameters of pregabalin and naproxen
大体时间:Predose and 30, 90, 180, 240, 360, and 420 minutes after dosing in each active treatment period

Plasma pharmacokinetic parameters, including AUClast, Clast, Cmax, and Tmax, for pregabalin and naproxen.

Predose and 30, 90, 180, 240, 360, and 420 minutes after dosing in each active treatment period

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Miroslav Backonja, M.D.、National Center for Complementary and Integrative Health (NCCIH)

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年11月18日

初级完成 (估计的)

2029年12月31日

研究完成 (估计的)

2030年12月31日

研究注册日期

首次提交

2026年4月23日

首先提交符合 QC 标准的

2026年4月23日

首次发布 (实际的)

2026年4月24日

研究记录更新

最后更新发布 (实际的)

2026年11月13日

上次提交的符合 QC 标准的更新

2026年11月12日

最后验证

2026年4月20日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

De-identified individual participant data underlying the results reported for this study may be shared upon request after completion of the primary endpoints. This may include baseline demographic and eligibility data, treatment sequence/assignment, pharmacodynamic data from the HEMP procedures and quantitative sensory testing (including VAS pain ratings from HCM, UVB, and cold pressor testing), pharmacokinetic concentration data and derived PK parameters, and safety data such as adverse events, vital signs, and clinical laboratory results. Data sharing will be handled by the PI or designee in accordance with NIH policies and applicable IRB/privacy requirements.

IPD 共享时间框架

Individual participant data may be available after completion of the primary endpoints. Requests may be made to the PI or designee after primary endpoint completion and will be considered in accordance with NIH policy, IRB approval, and applicable privacy/confidentiality requirements.

IPD 共享访问标准

De-identified individual participant data may be shared with qualified researchers after completion of the primary endpoints by request to the PI or designee. Requests should describe the proposed research question and analysis plan. Access will be considered in accordance with NIH policies, IRB requirements, and applicable privacy and confidentiality protections. Data will be shared only in a form that protects participant identity, by a mechanism determined by the NIH study team at the time of approval.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅